Arca
Skip to content

Sjogren's syndrome

Drug research and approvals for sjogren's syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 57 studies of sjogren's syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, and FDA has 1 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 57
  • Trials authorized in Canada: 10
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 57 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Jun 4, 2026A randomized, double-blind, placebo-controlled, multicenter phase 2a/b study assessing the efficacy, safety and tolerability of ddy391 in participants with…DDY391Novartis Pharmaceuticals CorporationOngoing
May 21, 2026A 52 week, 2 arm randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of ianalumab in patients with sjogren's disease with a…VAY736Novartis Pharmaceuticals CorporationOngoing
Aug 19, 2025A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of imvt- 1402 in…IMVT-1402IMMUNOVANT SCIENCES GMBHOngoing
Jun 17, 2025A randomized, placebo-controlled, double-blind, multicenter phase 3 protocol to assess the efficacy and safety of nipocalimab in adults with moderate to severe…JNJ-80202135 (NIPOCALIMAB)Johnson & JohnsonOngoing
Nov 20, 2024A phase 3 randomized, double-blinded, placebo-controlled multicenter trial with open-label extension to evaluate the efficacy, safety, and tolerability of…EFGARTIGIMOD (ARGX-113) PH20 SCargenx US, Inc.Ongoing
Mar 25, 2024A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dazodalibep in participants with sjogren's syndrome with…DAZODALIBEP (HZN-4920)AmgenOngoing
Sep 19, 2023A randomized, double-blind 2-arm neptunus extension study to access the long-term safety and efficacy of ianalumab in patients with sjogren's syndromeVAY736 (IANALUMAB)Novartis Pharmaceuticals CorporationOngoing
May 4, 2022A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active…VAY736Novartis Pharmaceuticals CorporationClosed
Aug 17, 2020A randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, pharmacokinetics, and therapeutic efficacy of sar441344 in…SAR441344SANOFI-AVENTIS CANADA INCClosed
Dec 20, 2019A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple cfz533 doses administered…CFZ533 (ISCALIMAB)Novartis Pharmaceuticals CorporationOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Feb 11, 1998SalagenTreatment of dry mouth in patients with Sjogren's syndrome.MGI Pharma, Inc.Approved
May 15, 1989BromhexineTreatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.Boehringer Ingelheim Pharmaceuticals, Inc.Designated
Nov 9, 1988Cyclosporine ophthalmicTreatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.University Of GeorgiaDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.